Larimar Therapeutics Validates Skin Biomarker in FA
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
